Press releases
These press releases are intended for journalists and analysts/investors.
-
Researcher’s work on ‘kiss of death’ protein gets industry accolades
Professor David Komander – Head of the Ubiquitin Signalling Division at WEHI – has won the 2023 GSK Award for Research Excellence (ARE).
-
Australians at risk of shingles have access to a newly funded vaccine
GSK Australia welcomes the listing of Shingrix on the National Immunisation Program.
-
This Pain Awareness Month, leading Geriatrician calls for greater awareness of shingles
GSK Australia recently commissioned a survey which has cast a spotlight on the lack of awareness surrounding shingles.
-
Experts remind to watch out for early signs of invasive meningococcal disease as we enter peak season
Professor Robert Booy is reminding Australians to stay vigilant for the signs and symptoms of invasive meningococcal disease (IMD).
-
Nucala® (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps
GSK Australia welcomes the PBS funding of Nucala for the treatment of severe chronic rhinosinusitis with nasal polyps.
-
New report: Adult vaccination - the shot in the arm Australia needs
Reforming Australia’s National Immunisation Program (NIP) to protect older Australians from disease.
-
GSK Australia advances support for emerging industry talent in third year of Graduate Researcher Program
GSK Australia is excited to announce the third year of its Graduate Researcher Program.
-
Australians 50 years of age and older urged not to downplay shingles risk
Health care professionals are using Shingles Awareness Week to educate people about the likelihood of being affected by shingles.
-
Test
Test
-
Leading Australian scientist at the forefront of genetic breast cancer research wins major industry award
Professor Georgia Chenevix-Trench wins the GSK Award for Research Excellence in 2022
-
Invasive meningococcal disease cases already surpassing 2021 total figures
GSK Australia helps raise community awareness of Invasive Meningococcal Disease (IMD).
-
Ovarian Cancer Therapy Zejula Newly Funded by Government
GSK Australia welcomes the Pharmaceutical Benefits Schedule (PBS) funding of niraparib.
-
Record number of sales roles open across the country at GSK Australia
Over 30 sales roles are currently open at GSK Australia, as the business continues on its exciting growth journey.
-
GSK Australia continues bridging skills gap between academic and industry with new cohort of Graduate Researchers
GSK Australia is delighted to announce the second year of its Graduate Researcher Program.
-
Enhanced parental leave policy increases support for working parents at GSK Australia and New Zealand
GSK Australia and New Zealand is proud to share the next evolution of its parental leave policy that ensures benefits
-
TRELEGY® ELLIPTA® listed on PBS for severe asthma
Single inhaler triple therapy for severe asthma reimbursed by the PBS in Australia
-
GSK Australia supports the Australian Red Cross Queensland and New South Wales Flood Appeal
GSK Australia supports the Australian Red Cross Queensland and New South Wales Flood Appeal
-
GSK & ViiV Healthcare: Our commitment to all LGBT+ communities
GSK & ViiV Healthcare: Our commitment to all LGBT+ communities
-
TGA approves Zejula for ovarian cancer providing another option for newly diagnosed women with this deadly disease
GSK Australia welcomes the Therapeutic Goods Administration (TGA) registration of niraparib.
-
Global innovation in intensive care research wins Australian duo GSK Award for Research Excellence
The 2021 GSK Award for Research Excellence was presented at Research Australia’s Health and Medical Research Awards in Sydney.
